Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase <scp>II JO25567</scp> study-Reference-Cited by-同舟云学术

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Published:2022-06-29 Issue:15 Volume:13 Page:2192-2200
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Hosomi Yukio¹^ORCID,Seto Takashi²,Nishio Makoto³,Goto Koichi⁴,Yamamoto Noboru⁵,Okamoto Isamu⁶,Tajima Kosei⁷,Kajihara Yusuke⁷,Yamamoto Nobuyuki⁸

Affiliation:

1. Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital Tokyo Japan

2. National Hospital Organization Kyushu Cancer Center Fukuoka Japan

3. The Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan

4. National Cancer Center Hospital East Kashiwa Japan

5. National Cancer Center Hospital Tokyo Japan

6. Department of Respiratory Medicine Graduate School of Medical Sciences, Kyushu University Fukuoka Japan

7. Chugai Pharmaceutical Co. Ltd. Tokyo Japan

8. Wakayama Medical University Wakayama Japan

Funder

Chugai Pharmaceutical

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14541

Reference35 articles.

1. Biological and clinical implications of EGFR mutations in lung cancer

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

4. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR‐mutated advanced non‐small‐cell lung;The Kaohsiung Journal of Medical Sciences;2024-03-25

3. Combination of Anti-Angiogenic and Systemic Therapy in Advanced Non-Small Cell Lung Cancer: Before and After Progression to Leptomeningeal Metastasis;2024-02-02

4. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-07-06

5. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial;JTO Clinical and Research Reports;2022-12